|
WO2020219640A1
|
|
Pyrimidine jak inhibitors for the treatment of skin diseases
|
|
WO2020219639A1
|
|
Ester and carbonate pyrimidine compounds as jak kinase inhibitors
|
|
WO2020154350A1
|
|
Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
|
|
WO2020123453A2
|
|
Naphthyridine and quinoline derivatives useful as alk5 inhibitors
|
|
CA3113667A1
|
|
2-azabicyclo hexane compound as jak inhibitor
|
|
US2020071323A1
|
|
Dimethyl amino azetidine amides as JAK inhibitors
|
|
US2020071325A1
|
|
5 to 7 membered heterocyclic amides as JAK inhibitors
|
|
WO2020051135A1
|
|
Process for preparing jak inhibitors and intermediates thereof
|
|
CA3053853A1
|
|
Dimethyl amino azetidine amides and 5 to 7 membered heterocyclic amides as jak inhibitors
|
|
US2020069667A1
|
|
Methods for treating chronic obstructive pulmonary disease
|
|
CN112204007A
|
|
Process for the preparation of 2- (1- (tert-butoxycarbonyl) piperidin-4-yl) benzoic acid
|
|
CR20200180A
|
|
Pyrimidine compound as jak kinase inhibitor
|
|
AU2018312349A1
|
|
Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
|
|
WO2019027881A1
|
|
Methods of treating symptoms of gastroparesis using velusetrag
|
|
CN110662747A
|
|
Glucuronide prodrugs of Janus kinase inhibitors
|
|
CN110662755A
|
|
Thiocarbamate prodrugs of tofacitinib
|
|
MX2019012945A
|
|
Crystalline forms of a jak inhibitor compound.
|
|
TW201841914A
|
|
Fused imidazo-piperidine jak inhibitor compound
|
|
US2018311226A1
|
|
Methods of treatment using a JAK inhibitor compound
|
|
EP3592742A1
|
|
Jak inhibitors containing a 4-membered heterocyclic amide
|
